CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
provide a better understanding of study drugs cetuximab (Erbitux®) and palbociclib when used in combination to treat patients with metastatic colon...
Phase 2
Chapel Hill, North Carolina, United States
(SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon...
Phase 3
Durham, North Carolina, United States and 250 other locations
with histologically or cytologically confirmed stage IV colorectal cancer coming form three different patient populations:* Cohort 1a: 6 pat...
Phase 1
Durham, North Carolina, United States and 11 other locations
of ST316 administered IV in subjects with selected advanced solid tumors likely to harbor abnormalities of the WNT/β-catenin signaling pathw...
Phase 1
Durham, North Carolina, United States and 6 other locations
with panitumumab in subjects with unresectable, refractory, KRAS/NRAS/BRAF wild-type, microsatellite stable (MSS) metastatic colorectal cancer...
Phase 2
Chapel Hill, North Carolina, United States and 4 other locations
is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors...
Phase 1
Durham, North Carolina, United States and 16 other locations
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor ...
Phase 1, Phase 2
Chapel Hill, North Carolina, United States and 83 other locations
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor...
Phase 2, Phase 3
Durham, North Carolina, United States and 904 other locations
Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET...
Phase 2
Chapel Hill, North Carolina, United States and 90 other locations
evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors...
Phase 1, Phase 2
Chapel Hill, North Carolina, United States and 219 other locations
Clinical trials
Research sites
Resources
Legal